Phaseline

Targets › SLC22A16

SLC22A16 (Solute carrier family 22 member 16): drug programs, companies and trials

6 programs from 4 companies in 7 trials: 5 Phase 3, 2 Phase 2; Oncology; next expected readout Feb 2027.

Facilitative organic cation transporter that mediates the transport of carnitine as well as the polyamine spermidine. Mediates the partially Na(+)-dependent bidirectional transport of carnitine. (UniProt, Q86VW1)

Open in Phaseline: the race on SLC22A16, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Centre Hospitalier Universitaire Dijonmodified FOLFOX
Multi-drug chemotherapy: folate antagonist (folinic acid), thymidylate synthase inhibitor
TOPO2, TYMS, DHFR, SLC22A16Phase 3Colon Cancer; Locally Advanced or Metastatic Small Bowel AdenocarcinomaFeb 2027
Tehran University of Medical SciencesDrug-Eluting Embolic Bead (DEBIRI)
Irinotecan-loaded drug-eluting beads for transarterial chemoembolization
SLC22A16Phase 3Liver NeoplasmOct 2027
Fudan UniversityXELOX adjuvant chemotherapy
Multi-agent chemotherapy: oxaliplatin (platinum agent) and capecitabine (5-fluorouracil pr
DHFR, TYMS, SLC22A16Phase 3High-risk Stage II Colorectal CancerJun 2028
Fudan UniversitymFOLFIRINOX adjuvant chemotherapy
Multi-agent chemotherapy: oxaliplatin (platinum agent), irinotecan (topoisomerase I inhibi
DHFR, TYMS, TOPO1, SLC22A16Phase 3High-risk Stage II Colorectal CancerJun 2028
Fudan UniversitymFOLFOX6 adjuvant chemotherapy
Multi-agent chemotherapy: oxaliplatin (platinum agent), leucovorin (folinic acid), and 5-f
DHFR, TYMS, SLC22A16Phase 3High-risk Stage II Colorectal CancerJun 2028
CRISM Therapeuticsirinotecan-ChemoSeed
Irinotecan-releasing implant for local chemotherapy in glioblastoma resection cavity
SLC22A16Phase 2GlioblastomaMay 2029

Conditions

High-risk Stage II Colorectal Cancer (3) Colon Cancer (1) Locally Advanced or Metastatic Small Bowel Adenocarcinoma (1) Glioblastoma (1) Liver Neoplasm (1)

Modalities

small molecule (5)

Companies

Fudan University (3) Centre Hospitalier Universitaire Dijon (1) CRISM Therapeutics (1) Tehran University of Medical Sciences (1)

Related targets

TYMS (4) DHFR (4) TOPO2 (1) TOPO1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.